Eduardo Mysler

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Josef S Smolen, Robert Landewé, J. W. J. Bijlsma et al. · Annals of the Rheumatic Diseases · 2020 · 2.8K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis

Gerald B. Appel, Gabriel Contreras, Mary Anne Dooley et al. · Journal of the American Society of Nephrology · 2009 · 1.1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study

Mark C. Genovese, James D. McKay, Eduardo Mysler et al. · Arthritis & Rheumatism · 2008 · 858 citations

Medicine, Pharmacology, Pharmacotherapy +16

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

Thomas J. Schnitzer, Gerd R Burmester, Eduardo Mysler et al. · The Lancet · 2004 · 702 citations

Medicine, Pharmacology, Pharmacotherapy +15